Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Petutschnigg

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Heart Failure|June 19, 2022
Closing the gap, or the beauty of alleviating our patients' symptomsJohannes Petutschnigg, Frank Edelmann
Der Internist|August 22, 2019
[Heart failure with preserved left ventricular ejection fraction]Johannes Petutschnigg, Frank Edelmann
ESC Heart Failure|January 28, 2020
Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trialDjawid Hashemi, Ludwig Dettmann, Tobias D Trippel, et al.
European Journal of Heart Failure|January 9, 2020
Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trialJohannes Petutschnigg, João Pedro Ferreira, Volker Holzendorf, et al.
ESC Heart Failure|February 10, 2021
The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF studyTobias Daniel Trippel, Meinhard Mende, Hans-Dirk Düngen, et al.
ESC Heart Failure|September 7, 2022
Evaluation of the HFA-PEFF Score: results from the prospective DIAST-CHF cohortDjawid Hashemi, Meinhard Mende, Tobias D Trippel, et al.
The American Journal of Cardiology|January 12, 2023
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)João Pedro Ferreira, John G F Cleland, Nicolas Girerd, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 24, 2022
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trialJoão Pedro Ferreira, John G F Cleland, Nicolas Girerd, et al.
European Journal of Internal Medicine|July 30, 2023
Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohortViktoria Santner, Hermann S Riepl, Florian Posch, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Heart Failure|June 19, 2022
Closing the gap, or the beauty of alleviating our patients' symptomsJohannes Petutschnigg, Frank Edelmann
Der Internist|August 22, 2019
[Heart failure with preserved left ventricular ejection fraction]Johannes Petutschnigg, Frank Edelmann
ESC Heart Failure|January 28, 2020
Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trialDjawid Hashemi, Ludwig Dettmann, Tobias D Trippel, et al.
European Journal of Heart Failure|January 9, 2020
Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trialJohannes Petutschnigg, João Pedro Ferreira, Volker Holzendorf, et al.
ESC Heart Failure|February 10, 2021
The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF studyTobias Daniel Trippel, Meinhard Mende, Hans-Dirk Düngen, et al.
ESC Heart Failure|September 7, 2022
Evaluation of the HFA-PEFF Score: results from the prospective DIAST-CHF cohortDjawid Hashemi, Meinhard Mende, Tobias D Trippel, et al.
The American Journal of Cardiology|January 12, 2023
Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)João Pedro Ferreira, John G F Cleland, Nicolas Girerd, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|October 24, 2022
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trialJoão Pedro Ferreira, John G F Cleland, Nicolas Girerd, et al.
European Journal of Internal Medicine|July 30, 2023
Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohortViktoria Santner, Hermann S Riepl, Florian Posch, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Pageof 3